Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PIK3C3 | Q8NEB9 | 16/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84506 | 0.83 | L3MBTL1 (0.52) | L3MBTL1PIK3C3JAK2JAK1TYK2 | |
| SCHEMBL20877691 | 0.79 | L3MBTL1 (0.47) | L3MBTL1PIK3C3JAK2JAK1TYK2 | |
| SCHEMBL3192275 | 0.78 | L3MBTL1 (0.55) | L3MBTL1PIK3C3NR3C2AR | |
| SCHEMBL2642302 | 0.73 | L3MBTL1 (0.55) | L3MBTL1PIK3C3JAK2JAK1TYK2 | |
| SCHEMBL13543138 | 0.71 | PIK3C3 (0.49) | L3MBTL1PIK3C3JAK2JAK1TYK2 | |
| SCHEMBL19736191 | 0.71 | L3MBTL1 (0.57) | L3MBTL1PIK3C3JAK2JAK1TYK2 | |
| SCHEMBL91475 | 0.71 | ALDH1A1 (0.60) | L3MBTL1PIK3C3 | |
| SCHEMBL2642300 | 0.71 | L3MBTL1 (0.57) | L3MBTL1PIK3C3JAK2JAK1TYK2 | |
| SCHEMBL13165570 | 0.71 | TYK2 (0.66) | L3MBTL1PIK3C3JAK2JAK1TYK2 | |
| SCHEMBL30441586 | 0.71 | L3MBTL1 (0.57) | L3MBTL1PIK3C3JAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10253027-B2 | Aryl lactam kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253027-B2 | Aryl lactam kinase inhibitors | AAK1, ADCK1, ANKK1 | L3MBTL1 2143/4885PIK3C3 430/4885JAK2 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.